Novo Nordisk Cuts Wegovy and Ozempic Self-Pay Price to $199 in New Access Push
Novo Nordisk has introduced a $199 introductory price for Wegovy and Ozempic starter doses, alongside a permanent drop in monthly self-pay costs to $349.
Athithi
EMA, CHMP NOVEMBER 2025 MEETING: TEN NEW APPROVALS, FOUR INDICATION EXTENSIONS
CHMP’s November 2025 meeting delivered 10 new drug approvals, four indication extensions, and several high-profile withdrawals, highlighting continued momentum in gene therapy, oncology, immunology, and diagnostics.
US CUTS SWISS TARIFFS TO 15% AS SWITZERLAND PLEDGES $200B INVESTMENTS
A stylized U.S. – Swiss handshake over rising economic indicators reflects the sweeping new trade deal tariffs slashed to 15% and Switzerland pledging $200B in U.S. investment through 2028. (Editorial Illustration) The United States and Switzerland have announced a major framework trade agreement that will see Washington slash tariffs on Swiss imports from 39% to … Read more
ABL Bio’s Grabody lands record heigh $2.6B deal with Lilly
ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.
Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul
Spanish health official displays a Ministry of Health certificate for asbestos-related injury, as Spain rolls out its new national certification system alongside expanded neonatal screening reforms. (Editorial illustration.) CISNS approves sweeping updates to neonatal diagnostics and formalizes a nationwide system to certify asbestos-related disease for compensation Spain’s Interterritorial Council of the National Health System (CISNS) … Read more
FDA Unveils Plausible Mechanism Pathway to Accelerate Bespoke Gene Editing Therapies
FDA officials Vinay Prasad and Marty Makary have unveiled a new “plausible mechanism pathway” designed to accelerate bespoke gene-editing therapies.
Lilly Doubles Down on Genetic Medicines with $1.6B RNAi and Gene Therapy Alliances
Eli Lilly has signed back-to-back collaborations with SanegeneBio and MeiraGTx, advancing its genetic medicine portfolio across RNA interference and ophthalmic gene therapy. Together, the agreements deepen Lilly’s position in next-generation RNA- and DNA-based therapeutics.
CMS’ Medicaid drug payment model brings Trump’s MFN push
CMS’ Medicaid drug payment model links value-based pricing and international benchmarks to lower costs and improve patient outcomes. (Editorial illustration.) US government aims to lower Medicaid drug prices and align costs with global rates under new GENEROUS model The US government has launched a sweeping initiative to reduce prescription drug costs under the Medicaid program, … Read more
Thailand launches drug access program to slash household medical bills by 32B baht
Thailand is letting patients fill hospital prescriptions at registered pharmacies under a new initiative expected to save households 32 billion baht annually. Officials say the program will ease private-sector pricing pressure and improve drug access nationwide.
Scilex Secures Exclusive Global License for Tokenizing Biotech Assets Through Datavault AI Platform
Scilex Holding Company has announced an exclusive global license from Datavault AI to tokenize and monetize genomic, diagnostic, and therapeutic data ushering in a new digital framework for valuing real-world biotech assets. The agreement allows Scilex to use Datavault’s proprietary AI-driven platform to create a Biotech Exchange, a marketplace designed to securely trade and fund … Read more